Trial Profile

A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy (NIVORAD)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms NIVORAD
Sponsors Bristol-Myers Squibb

Most Recent Events

01 Apr 2026 Primary endpoint has been met. (Progression free survival (PFS) at 6 months (RECIST 1.1))
01 Apr 2026 Results published in the International Journal of Radiation Oncology, Biology, Physics
11 Jul 2019 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com